The Crosstalk Between Calcium-sensing Receptor Signaling and Endocannabinoid System in Primary Hyperparathyroidism
Targeting CaSR
1 other identifier
observational
90
1 country
1
Brief Summary
Despite the strong association of hyperparathyroidism with arachidonic acid related lipid signals, little research has been performed over the years. A better understanding of the link between arachidonic acid remodeling, prostaglandin and endocannabinoid production with primary hyperparathyroidism in primary tissue/cells might open up new avenues for biomarker and thus to a potential therapeutic target. Arachidonic acid remodeling might also have an impact on depression and elevated cytokines in patients with primary hyperparathyroidism. The investigators therefore will assess the correlation between postoperative improvement of PHQ-9 and cytokine levels with arachidonic acid remodeling.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Feb 2019
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 25, 2019
CompletedStudy Start
First participant enrolled
February 1, 2019
CompletedFirst Posted
Study publicly available on registry
February 6, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 31, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
July 31, 2022
CompletedJanuary 26, 2023
January 1, 2023
3.5 years
January 25, 2019
January 24, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Activity-based protein profiling (ABPP) will be used to assess the enzymes involved in calcium induced stress signals and endocannabinoid activation
2 months
Secondary Outcomes (8)
Measurement of the level of parathyroid hormone
2 months
Measurement of the level of calcium
2 months
Measurement of the level of cortisol
2 months
Measurement of the level of 25-hydroxyvitamin D
2 months
Measurement of the levels of the enzymes involved in the endocannabinoid system activation (diacylglycerol lipase; monoacylglycerol lipase, phospholipases, cyclooxygenases)
2 months
- +3 more secondary outcomes
Eligibility Criteria
Primary hyperparathyroidism with planned surgery
You may qualify if:
- Age ≥ 18 years
- Primary hyperparathyroidism with planned surgery
- Written informed consent
You may not qualify if:
- Age \<18 years
- Secondary/tertiary hyperparathyroidism
- Renal insufficiency
- Participant is pregnant
- Participant is incapable of giving an informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of visceral surgery and transplant surgery, Berne University Hospital
Bern, 3010, Switzerland
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Reto Kaderli, MD
Insel Gruppe AG, University Hospital Bern
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 2 Months
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 25, 2019
First Posted
February 6, 2019
Study Start
February 1, 2019
Primary Completion
July 31, 2022
Study Completion
July 31, 2022
Last Updated
January 26, 2023
Record last verified: 2023-01